NT5E and type 1 diabetes mellitus: BAFFR-Fc decreases T1DM procession by expanding CD73+ B lymphocytes and reduces side effects of anti-CD20 (15), suggesting that CD73 plays a key role in reducing side effects of B lymphocyte-targeted therapies.